Slow Bull
The market, slowly. FRIDAY, 25 SEPTEMBER 2026
← All news
Markets

Novo pursues long-acting obesity drugs; Acadia slumps on Alzheimer’s data

1 source ·1 article ·1h ago

Novo’s latest alliance involves injectables given every one to three months. Elsewhere, Nektar won a legal spat with Eli Lilly and the FDA issued two approvals.

Covered by 1 outlet

Biopharmadive 1

All coverage · 1 article

BioPharma Dive ·1h ago

Novo pursues long-acting obesity drugs; Acadia slumps on Alzheimer’s data

Novo’s latest alliance involves injectables given every one to three months. Elsewhere, Nektar won a legal spat with Eli Lilly and the FDA issued two approvals.